115 results
Page 2 of 6
6-K
EX-99.2
wvtji133 eixdo
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.1
0mbz77s4 5cpf98wek
2 May 22
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
7:00am
6-K
EX-99.1
7qiej38j9u3s bifo9r
25 Apr 22
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH
7:00am
6-K
EX-99.1
e0qibh3lw1 6n
22 Mar 22
Current report (foreign)
7:28am
6-K
EX-99.1
dfzf8vsvfrztqjj
10 Mar 22
ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
7:11am
424B7
x1pmh
3 Mar 22
Prospectus with selling stockholder info
4:43pm
F-3
65ppzf ma
17 Feb 22
Shelf registration (foreign)
4:14pm
6-K
EX-99.1
v50 xb4zq2v
10 Feb 22
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
4:27pm
6-K
EX-99.1
dplsb3ut
6 Jan 22
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
6:30am
6-K
EX-99.1
ihg8ptqeh
17 Dec 21
ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:15am
6-K
EX-99.1
rvnb0g5aye4q820fn8
10 Dec 21
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
8:12am
424B7
948otjq
23 Nov 21
Prospectus with selling stockholder info
4:06pm
6-K
EX-99.2
9tt6ivlypmyqj
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
6-K
EX-99.1
hmndped terk1u
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
F-3
8uegtav5idxiwyset
10 Nov 21
Shelf registration (foreign)
5:23pm
6-K
EX-99.3
xc7504ihmaj7fvgf8k8o
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am
6-K
EX-99.2
we71pi 6yo1
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am